• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Tagged: report

  • Audio Journal of Oncology Volume 16 Number 11 0
    • in Oncology
    • — 3 Jun, 2008

    Audio Journal of Oncology Volume 16 Number 11

    Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)

    Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology Annual Meeting, May 30-June 3, 2008, Chicago

    Michael Gnant
    Michael Gnant

    In this edition:

    1. Zoledronic …

    Read more
    Risks From Stopping Cancer Trials Early! 0
    • in London School of Hygiene & Tropical Medicine
    • — 9 Apr, 2008

    Risks From Stopping Cancer Trials Early!

    Giovanni Apolone
    Giovanni Apolone

    In this edition of Audio News, presented by Peter Goodwin, Giovanni Apolone (Mario Negri Institute, Milan) and Stuart Pocock (London School of Hygiene and Tropical Medicine), talk about:

    Risks From Stopping Cancer Trials Early!
    – A report from

    …
    Read more
  • Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma? 0
    • in General Medicine
    • — 27 Feb, 2008

    Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma?

    Timothy Illidge
    Timothy Illidge

    Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
    TIMOTHY ILLIDGE, Christie Hospital, Manchester
    Radioconjugated antibodies are showing great promise for treating follicular lymphoma which has failed chemotherapy combined with rituximab. That’s according to Tim
    …
    Read more
    Adjuvant Chemoradiotherapy: Big Gains In Pancreas Cancer 0
    • in Oncology
    • — 27 Jan, 2008

    Adjuvant Chemoradiotherapy: Big Gains In Pancreas Cancer

    Charles Hsu
    Charles Hsu

    CHARLES HSU, Johns Hopkins University, Baltimore
    Big improvements in overall survival were achieved by combining radiation with adjuvant chemotherapy for patients with pancreas cancer in a dtudy reported to the conference in Orlando. Charles Hsu told Peter Goodwin
    …
    Read more
    • in Oncology
    • — 11 Dec, 2007

    Live Report from ASH:
    Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

    Anton Hagenbeek
    Anton Hagenbeek

    ANTON HAGENBEEK, University Medical Centre Utrecht
    For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH
    …
    Read more
    • in Oncology
    • — 11 Dec, 2007

    Live Report from ASH:
    Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?

    Christian Geisler
    Christian Geisler

    CHRISTIAN GEISLER, Rigshospitalet, Copenhagen
    Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek Thorne got the details on the study – which featured an intensive immunochemotherapy
    …
    Read more
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH:
    Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

    Susan O’Brien
    Susan O’Brien

    SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
    For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology
    …
    Read more
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH:
    Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML

    Richard Stone
    Richard Stone

    RICHARD STONE, Dana-Farber Cancer Institute, Boston
    GEORGE CANELLOS, Dana-Farber Cancer Institute

    New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where
    …
    Read more
  • Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes 0
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes

    Pierre Fenaux
    Pierre Fenaux

    PIERRE FENAUX, Paris 13 University
    Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University
    …
    Read more
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH:
    Interleukin-2 For Acute Myeloid Leukemia In First Remission?

    Jonathan Kolitz
    Jonathan Kolitz

    JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
    GEORGE CANELLOS, Dana-Farber Cancer Institute

    For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim
    …
    Read more
  • TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention? 0
    • in Cardiovascular
    • — 5 Nov, 2007

    TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?

    Gordon Tomaselli
    Gordon Tomaselli
    Daniel Jones
    Daniel Jones

    REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
    GORDON TOMASELLI, Johns Hopkins University, Baltimore
    COMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, Jackson

    A potential new
    …
    Read more
    BORIS: A. baumanni Highly Resistant β-Lactamase and Varying Susceptibility Patterns 0
    • in General Medicine
    • — 21 Sep, 2007

    BORIS: A. baumanni Highly Resistant β-Lactamase and Varying Susceptibility Patterns

    Jennifer Lavrrar, Jane Hata, Jeanette Block
    Jennifer Lavrrar, Jane Hata, Jeanette Block

    REFERENCE: Slide Session C2-1360, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
    JANE HATA, bioMéríeux Inc, Durham
    Reports from the BORIS study call for ongoing surveillance of multi-drug resistant Acinetobacter
    …
    Read more
  • Next Page »
  • Sign up for AudioMedica.com news

    * = required field
    Speciality




  • Home
  • Tagged: report

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.